Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
NORTH PALM BEACH, FL / ACCESSWIRE / August 22, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Benzinga: Why NBIO is a Biotech Bargain Basement Deal with Underappreciated Potential
We came across Nascent Biotech Inc. NBIO last year and it caught our eye despite still trading on the OTC for just pennies per share. The share price of a stock isn’t a very important [...]
Journal of Clinical Oncology: Phase 1 study of pritumumab in brain cancer.
Jose Arganda Carrillo, Santosh Kesari, Jaya Mini Gill, Charles Redfern, Sean Carrick, Ivan Babic Background: Pritumumab, a fully human IgG1 (kappa) monoclonal antibody (mAb), was originally [...]
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
NORTH PALM BEACH, FL / ACCESSWIRE / April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Announces the Completion of Its Phase 1 Clinical Trials
NORTH PALM BEACH, FL / ACCESSWIRE / February 28, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
NORTH PALM BEACH, FL / ACCESSWIRE / January 10, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
VERO BEACH, FL / ACCESSWIRE / November 1, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
VERO BEACH, FL / ACCESSWIRE / October 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]